Evidence map›Paper›PMID 38634143›Full record

ArticleHaematologica2024

Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia.

Matthew P Connor, Neeharika Prathapa, Noelle V Frey, Saar I Gill, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine E Lai, Alison W Loren, Selina M Luger, Andrew H Matthews and 8 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Matthew P ConnorDivision of Hematology-Oncology, Department of Medicine, University of Pennsylvania. matthew.connor@pennmedicine.upenn.edu.
Neeharika PrathapaDivision of Hematology-Oncology, Department of Medicine, University of Pennsylvania.
Noelle V FreyDivision of Hematology-Oncology, Department of Medicine, University of Pennsylvania.
Saar I GillDivision of Hematology-Oncology, Department of Medicine, University of Pennsylvania.
Elizabeth O HexnerDivision of Hematology-Oncology, Department of Medicine, University of Pennsylvania.
Ximena Jordan BrunoDivision of Hematology-Oncology, Department of Medicine, University of Pennsylvania.
Catherine E LaiDivision of Hematology-Oncology, Department of Medicine, University of Pennsylvania.
Alison W LorenDivision of Hematology-Oncology, Department of Medicine, University of Pennsylvania.
Selina M LugerDivision of Hematology-Oncology, Department of Medicine, University of Pennsylvania.
Andrew H MatthewsDivision of Hematology-Oncology, Department of Medicine, University of Pennsylvania.
Shannon R McCurdyDivision of Hematology-Oncology, Department of Medicine, University of Pennsylvania.
Alexander E PerlDivision of Hematology-Oncology, Department of Medicine, University of Pennsylvania.
David L PorterDivision of Hematology-Oncology, Department of Medicine, University of Pennsylvania.
Arlene ZeringueInformation Services, University of Pennsylvania.
Joseph H OvedDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York City, NY; Comprehensive Bone Marrow Failure Center, Children's Hospital of Philadelphia.
Timothy S OlsonComprehensive Bone Marrow Failure Center, Children's Hospital of Philadelphia, Philadelphia, PA; Department of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia.
Keith W PratzDivision of Hematology-Oncology, Department of Medicine, University of Pennsylvania.
Daria V BabushokDivision of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA; Comprehensive Bone Marrow Failure Center, Children's Hospital of Philadelphia. daria.babushok@pennmedicine.upenn.edu.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
CANCER CLINICAL EPIDEMIOLOGY TRAINING GRANTT32CA009679 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Richard Aplenc, Karen Glanz · 1992 to 2026
$11.1M
The effects of somatic HLA class I allele mutations on antigen presentation in acquired aplastic anemiaR03HL160678 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI BABUSHOK, DARIA · 2022 to 2023
$163k
NCI NIH HHS P30 CA008748NCI NIH HHS T32 CA009679NHLBI NIH HHS R03 HL160678
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anemia, AplasticAdultAgedAged, 80 and overAntimetabolites, AntineoplasticAzacitidineDNA MethylationFemaleHumansMaleMiddle AgedMyelodysplastic SyndromesNeoplasms, Second PrimaryAntimetabolites, AntineoplasticAzacitidine

Identifiers

PMID38634143
PMCPMC11290501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.